Collegium Pharmaceutical Inc (COLL) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Collegium Provides 2025 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Collegium Reports Record Third Quarter 2024 Financial Results

– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca®...

Form 8-K - Current report

Collegium Appoints Vikram Karnani as Chief Executive Officer

STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading...

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities